search
Back to results

Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial (CuPRAC)

Primary Purpose

Cervical Cancer

Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Curcumin
Palliative radiotherapy
Sponsored by
Addis Ababa University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Cancer focused on measuring Curcumin, Cervical cancer, Radiosensitizer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion criteria: Age >18 years old (Adult, Older Adult) Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IIIB-IVA Undergoing for standard of care palliative radiotherapy without chemotherapy as per the local treatment guideline Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 Adequate liver function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (Upper Limit of Normal); total serum bilirubin ≤1.5 x ULN); blood cell counts (absolute neutrophils count ≥1.500/mm3; platelet count ≥100.000/mm3; hemoglobin ≥10.0 g/dL); renal function (serum creatinine ≤1.5 x ULN; estimate creatinine clearance (Cockcroft-Gault) ≥60 mL/min) Participants must have measureable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1. Agree to use an effective form of contraception (e.g., true abstinence (not periodic abstinence), barrier contraception, highly effective hormonal contraception) if the participant is of child bearing age Give informed consent Exclusion criteria: Cervical cancer patients who are candidates for single dose palliative radiotherapy Patients with hydronephrosis Evidence of distant metastases Receiving any other investigational agent concurrently or within the last 4 weeks before enrollment Received any previous radiation or chemotherapy for cervical cancer Underwent surgery in the four weeks prior to the enrolment date or scheduled to undergo surgery within eight weeks after end of treatment Currently using of any chemotherapy or scheduled to receive within eight weeks after end of treatment Known allergy to turmeric or its derivatives (ginger, curry, cumin, or cardamom) Known allergy to fenugreek, peanut, soy, lentil, pea, bean, and chickpea Presence of conditions that precludes the safe administration of the trial intervention and/or prohibit adequate compliance to study requirements including chronic ongoing infections (like HIV, Hepatitis B or C), uncontrolled hypertension, heart failure, cardiac arrhythmia, unstable angina, chronic obstructive lung disease, diabetes mellitus, chronic renal disease, chronic liver disease, biliary tract obstruction or cholelithiasis, gastric or duodenal ulcers, autoimmune or inflammatory disorders, a coagulation or platelet disorder, seizure disorders and psychiatric illness. Patients with disorders other than the ones specified above may also be excluded based on the judgment of the principal investigator. Pregnant and breastfeeding women Participants with circumstances that will not permit completion of the study or required follow-up. For instance, if travel to and from treatment site is an issue.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Concurrent Curcumin Palliative Radiotherapy

    Arm Description

    Daily 1000 mg oral CGM Curcumin in two divided doses for seven days prior to the start of and for three to five weeks concurrently with palliative radiotherapy.

    Outcomes

    Primary Outcome Measures

    Proportion of participants without treatment-related toxicities leading to premature termination of treatment
    Objective Response Rate (ORR)
    Objective Response Rate is defined as proportion of participants having a complete response (CR) or partial response (PR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
    Incidence of Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
    Any new or worsening of a pre-existing untoward sign, symptom, or disease, including a clinically significant laboratory or vital sign abnormality during study treatment, is defined as a treatment emergent adverse event.
    Incidence of Dose Interruption in curcumin and radiotherapy regimens
    A Dose Interruption is defined a zero dose given on one or more days on which the protocol-specified dose is non-zero, followed by resumption of dosing.
    Incidence of Dose Reduction in curcumin and radiotherapy regimens
    A dose reduction is a decrease in dose from the protocol planned starting dose or a decrease from the previous non-zero dose, even if this decrease has been directly preceded by an interruption.
    Dose Intensity (DI) of curcumin and radiotherapy
    Dose intensity is defined as cumulative dose divided by the treatment duration in weeks.
    Relative Dose Intensity (RDI) of curcumin and radiotherapy
    Relative dose intensity is defined as dose intensity (actual DI) divided by the protocol weekly dose (planned DI), expressed as a percentage.

    Secondary Outcome Measures

    Disease Control Rate (DCR)
    Disease control rate (DCR): proportion of participants having a complete response (CR) or partial response (PR) or stable disease (SD) as defined by the RECIST 1.1 criteria.
    Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 7-9 weeks
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) measures quality of life in cancer patients by evaluating physical, psychological, and social functions. Possible scores range from zero to 100, with a higher scale score indicating a higher response level. As such, high scores on functional and global health status (QoL) scales indicate healthy levels of functioning and high quality of life, respectively. However, a high score on the symptoms scale or item indicates more problems or symptomatology.
    Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 13-17 weeks
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) measures quality of life in cancer patients by evaluating physical, psychological, and social functions. Possible scores range from zero to 100, with a higher scale score indicating a higher response level. As such, high scores on functional and global health status (QoL) scales indicate healthy levels of functioning and high quality of life, respectively. However, a high score on the symptoms scale or item indicates more problems or symptomatology.
    Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 7-9 weeks
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module (EORTC QLQ-CX24) measures quality of life in cervical cancer patients in combination with the QLQ-C30. Possible scores range from zero to 100 for all scale and single-item measures. While a high score on the functional single-items indicates a high degree of functioning, a high score on the symptom scales or single-items indicates a high level of symptomatology or difficulties.
    Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 13-17 weeks
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module (EORTC QLQ-CX24) measures quality of life in cervical cancer patients in combination with the QLQ-C30. Possible scores range from zero to 100 for all scale and single-item measures. While a high score on the functional single-items indicates a high degree of functioning, a high score on the symptom scales or single-items indicates a high level of symptomatology or difficulties.
    Peak Plasma Concentration (Cmax) of CGM Curcumin
    Peak Plasma Concentration represents the highest observed curcumin concentration observed in plasma over all PK sample concentrations following single-dose CGM Curcumin administration.
    Time to Peak Plasma Concentration (Tmax) of CGM Curcumin
    Time to Peak Plasma Concentration (Tmax) represents the time when Cmax of curcumin occurs following single-dose CGM Curcumin administration.
    Area under the Plasma Concentration versus Time Curve (AUCτ) of CGM Curcumin
    Area under the Plasma Concentration versus Time Curve (AUCτ) represents the area under the concentration-time curve of curcumin from time zero to the time of the end of dosing interval following single-dose CGM Curcumin administration.
    Half-life (T1/2) of CGM Curcumin
    Half-life (T1/2) represents the time for plasma concentration of curcumin to fall by a factor of one-half in the terminal phase following single-dose CGM Curcumin administration.
    Recruitment Rate
    Recruitment Rate is defined as the proportion of those who participate in the trial who were approached as potential participants.
    Assessment Completion Rate
    Assessment Completion Rate is defined as the proportion of assessments that could be completed as planned.
    Attrition Rate
    Attrition Rate is defined as the proportion of participants who withdraw from the study.

    Full Information

    First Posted
    June 21, 2023
    Last Updated
    July 14, 2023
    Sponsor
    Addis Ababa University
    Collaborators
    Center for Innovative Drug Development and Therapeutic Trials for Africa, Addis Ababa University, Akay Natural Ingredients Private Limited
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05947513
    Brief Title
    Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial
    Acronym
    CuPRAC
    Official Title
    Feasibility, Safety, and Efficacy of Concomitant Curcumin in Patients Undergoing Palliative Radiotherapy for FIGO Stage IIIB-IVA Cervical Cancer: An Open-label Pilot Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 2023 (Anticipated)
    Primary Completion Date
    November 2024 (Anticipated)
    Study Completion Date
    November 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Addis Ababa University
    Collaborators
    Center for Innovative Drug Development and Therapeutic Trials for Africa, Addis Ababa University, Akay Natural Ingredients Private Limited

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are: Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe? Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses? How much curcumin is absorbed into the body and how long will it stay in the body? Participants will: Take two 500 mg curcumin capsules twice per day for 4-6 weeks in addition to the prescribed palliative radiotherapy. Provide blood and urine samples for laboratory tests. Provide blood samples to measure curcumin levels in their body. Obtain CT-scan to measure their tumor response. Complete questioners to measure improvements to their quality of life, if any.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cervical Cancer
    Keywords
    Curcumin, Cervical cancer, Radiosensitizer

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    19 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Concurrent Curcumin Palliative Radiotherapy
    Arm Type
    Experimental
    Arm Description
    Daily 1000 mg oral CGM Curcumin in two divided doses for seven days prior to the start of and for three to five weeks concurrently with palliative radiotherapy.
    Intervention Type
    Drug
    Intervention Name(s)
    Curcumin
    Other Intervention Name(s)
    Curcumagalactomannoside (CGM), CurQfen
    Intervention Description
    Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.
    Intervention Type
    Radiation
    Intervention Name(s)
    Palliative radiotherapy
    Other Intervention Name(s)
    Non-radical radiotherapy
    Intervention Description
    As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.
    Primary Outcome Measure Information:
    Title
    Proportion of participants without treatment-related toxicities leading to premature termination of treatment
    Time Frame
    From initiation (Day 1) up to end of treatment over 4-6 weeks
    Title
    Objective Response Rate (ORR)
    Description
    Objective Response Rate is defined as proportion of participants having a complete response (CR) or partial response (PR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
    Time Frame
    Time Frame: 13-17 weeks
    Title
    Incidence of Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
    Description
    Any new or worsening of a pre-existing untoward sign, symptom, or disease, including a clinically significant laboratory or vital sign abnormality during study treatment, is defined as a treatment emergent adverse event.
    Time Frame
    Up to 10-14 weeks from treatment initiation
    Title
    Incidence of Dose Interruption in curcumin and radiotherapy regimens
    Description
    A Dose Interruption is defined a zero dose given on one or more days on which the protocol-specified dose is non-zero, followed by resumption of dosing.
    Time Frame
    From initiation (Day 1) up to end treatment over 4-6 weeks
    Title
    Incidence of Dose Reduction in curcumin and radiotherapy regimens
    Description
    A dose reduction is a decrease in dose from the protocol planned starting dose or a decrease from the previous non-zero dose, even if this decrease has been directly preceded by an interruption.
    Time Frame
    From initiation (Day 1) up to end treatment over 4-6 weeks
    Title
    Dose Intensity (DI) of curcumin and radiotherapy
    Description
    Dose intensity is defined as cumulative dose divided by the treatment duration in weeks.
    Time Frame
    From initiation (Day 1) up to end treatment over 4-6 weeks
    Title
    Relative Dose Intensity (RDI) of curcumin and radiotherapy
    Description
    Relative dose intensity is defined as dose intensity (actual DI) divided by the protocol weekly dose (planned DI), expressed as a percentage.
    Time Frame
    From initiation (Day 1) up to end treatment over 4-6 weeks
    Secondary Outcome Measure Information:
    Title
    Disease Control Rate (DCR)
    Description
    Disease control rate (DCR): proportion of participants having a complete response (CR) or partial response (PR) or stable disease (SD) as defined by the RECIST 1.1 criteria.
    Time Frame
    13-17 weeks
    Title
    Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 7-9 weeks
    Description
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) measures quality of life in cancer patients by evaluating physical, psychological, and social functions. Possible scores range from zero to 100, with a higher scale score indicating a higher response level. As such, high scores on functional and global health status (QoL) scales indicate healthy levels of functioning and high quality of life, respectively. However, a high score on the symptoms scale or item indicates more problems or symptomatology.
    Time Frame
    Baseline, 7-9 weeks
    Title
    Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 13-17 weeks
    Description
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) measures quality of life in cancer patients by evaluating physical, psychological, and social functions. Possible scores range from zero to 100, with a higher scale score indicating a higher response level. As such, high scores on functional and global health status (QoL) scales indicate healthy levels of functioning and high quality of life, respectively. However, a high score on the symptoms scale or item indicates more problems or symptomatology.
    Time Frame
    Baseline, 13-17 weeks
    Title
    Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 7-9 weeks
    Description
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module (EORTC QLQ-CX24) measures quality of life in cervical cancer patients in combination with the QLQ-C30. Possible scores range from zero to 100 for all scale and single-item measures. While a high score on the functional single-items indicates a high degree of functioning, a high score on the symptom scales or single-items indicates a high level of symptomatology or difficulties.
    Time Frame
    Baseline, 7-9 weeks
    Title
    Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 13-17 weeks
    Description
    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module (EORTC QLQ-CX24) measures quality of life in cervical cancer patients in combination with the QLQ-C30. Possible scores range from zero to 100 for all scale and single-item measures. While a high score on the functional single-items indicates a high degree of functioning, a high score on the symptom scales or single-items indicates a high level of symptomatology or difficulties.
    Time Frame
    Baseline, 13-17 weeks
    Title
    Peak Plasma Concentration (Cmax) of CGM Curcumin
    Description
    Peak Plasma Concentration represents the highest observed curcumin concentration observed in plasma over all PK sample concentrations following single-dose CGM Curcumin administration.
    Time Frame
    Pre-dose and 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose
    Title
    Time to Peak Plasma Concentration (Tmax) of CGM Curcumin
    Description
    Time to Peak Plasma Concentration (Tmax) represents the time when Cmax of curcumin occurs following single-dose CGM Curcumin administration.
    Time Frame
    Pre-dose and 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose
    Title
    Area under the Plasma Concentration versus Time Curve (AUCτ) of CGM Curcumin
    Description
    Area under the Plasma Concentration versus Time Curve (AUCτ) represents the area under the concentration-time curve of curcumin from time zero to the time of the end of dosing interval following single-dose CGM Curcumin administration.
    Time Frame
    Pre-dose and 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose
    Title
    Half-life (T1/2) of CGM Curcumin
    Description
    Half-life (T1/2) represents the time for plasma concentration of curcumin to fall by a factor of one-half in the terminal phase following single-dose CGM Curcumin administration.
    Time Frame
    Pre-dose and 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose
    Title
    Recruitment Rate
    Description
    Recruitment Rate is defined as the proportion of those who participate in the trial who were approached as potential participants.
    Time Frame
    through study completion, an average of 1 year
    Title
    Assessment Completion Rate
    Description
    Assessment Completion Rate is defined as the proportion of assessments that could be completed as planned.
    Time Frame
    through study completion, an average of 1 year
    Title
    Attrition Rate
    Description
    Attrition Rate is defined as the proportion of participants who withdraw from the study.
    Time Frame
    through study completion, an average of 1 year

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion criteria: Age >18 years old (Adult, Older Adult) Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IIIB-IVA Undergoing for standard of care palliative radiotherapy without chemotherapy as per the local treatment guideline Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 Adequate liver function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (Upper Limit of Normal); total serum bilirubin ≤1.5 x ULN); blood cell counts (absolute neutrophils count ≥1.500/mm3; platelet count ≥100.000/mm3; hemoglobin ≥10.0 g/dL); renal function (serum creatinine ≤1.5 x ULN; estimate creatinine clearance (Cockcroft-Gault) ≥60 mL/min) Participants must have measureable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1. Agree to use an effective form of contraception (e.g., true abstinence (not periodic abstinence), barrier contraception, highly effective hormonal contraception) if the participant is of child bearing age Give informed consent Exclusion criteria: Cervical cancer patients who are candidates for single dose palliative radiotherapy Patients with hydronephrosis Evidence of distant metastases Receiving any other investigational agent concurrently or within the last 4 weeks before enrollment Received any previous radiation or chemotherapy for cervical cancer Underwent surgery in the four weeks prior to the enrolment date or scheduled to undergo surgery within eight weeks after end of treatment Currently using of any chemotherapy or scheduled to receive within eight weeks after end of treatment Known allergy to turmeric or its derivatives (ginger, curry, cumin, or cardamom) Known allergy to fenugreek, peanut, soy, lentil, pea, bean, and chickpea Presence of conditions that precludes the safe administration of the trial intervention and/or prohibit adequate compliance to study requirements including chronic ongoing infections (like HIV, Hepatitis B or C), uncontrolled hypertension, heart failure, cardiac arrhythmia, unstable angina, chronic obstructive lung disease, diabetes mellitus, chronic renal disease, chronic liver disease, biliary tract obstruction or cholelithiasis, gastric or duodenal ulcers, autoimmune or inflammatory disorders, a coagulation or platelet disorder, seizure disorders and psychiatric illness. Patients with disorders other than the ones specified above may also be excluded based on the judgment of the principal investigator. Pregnant and breastfeeding women Participants with circumstances that will not permit completion of the study or required follow-up. For instance, if travel to and from treatment site is an issue.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Biniyam Girma, Bpharm, MSc
    Phone
    093-708-9518
    Ext
    251
    Email
    biniyam.girma@ju.edu.et
    First Name & Middle Initial & Last Name or Official Title & Degree
    Michele Joseph, MSc, MPH
    Phone
    092-914-2593
    Ext
    251
    Email
    michele.joseph@aau.edu.et
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Eyasu Makonnen, Bpharm, PhD
    Organizational Affiliation
    Addis Ababa University
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Biniyam Girma, Bpharm, MSc
    Organizational Affiliation
    Addis Ababa University
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Wondemagegnehu Tigeneh, MD, MMed(RT)
    Organizational Affiliation
    Addis Ababa University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial

    We'll reach out to this number within 24 hrs